Royalty Pharma plc (RPRX) FY2024 Annual Statement of Cash Flows

Income StatementCash FlowBalance Sheet

Statement of Cash Flows

2024-01-01 to 2024-12-31

Swipe to see the full flow
Royalty Pharma plc cash flow reconciliation, Jan 1, 2024 through Dec 31, 2024One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Identified asset purchases, sales and maturities are blue in either cash direction. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Read chart description and values below for full signed amounts, including zero items.Cash collections from financial royalty assets → operating reconciliation: $2,983,410,000.00Other royalty cash collections → operating reconciliation: $108,846,000.00Interest received → operating reconciliation: $46,482,000.00Cash collections from intangible royalty assets → operating reconciliation: $14,647,000.00Distributions from equity method investees → operating reconciliation: $13,396,000.00operating reconciliation → Net cash from operating activities: $2,768,986,000.00operating reconciliation → Payments for operating and professional costs: $236,225,000.00operating reconciliation → Interest paid: $159,570,000.00operating reconciliation → Development-stage funding payments - ongoing: $2,000,000.00Proceeds from issuance of long-term debt, net of discount → financing reconciliation: $1,471,235,000.00Contributions from non-controlling interests - other → financing reconciliation: $4,360,000.00Contributions from legacy non-controlling interests - R&D → financing reconciliation: $747,000.00financing reconciliation → Net cash from financing activities: $361,145,000.00financing reconciliation → Dividends to shareholders: $376,465,000.00financing reconciliation → Distributions to legacy non-controlling interests - Portfolio Receipts: $362,280,000.00financing reconciliation → Repurchases of Class A ordinary shares: $229,651,000.00financing reconciliation → Distributions to continuing non-controlling interests: $125,159,000.00financing reconciliation → Debt issuance costs and other: $12,616,000.00financing reconciliation → Other: $9,026,000.00Proceeds from equity securities → investing reconciliation: $98,575,000.00Distributions from equity method investees → investing reconciliation: $23,641,000.00Proceeds from available for sale debt securities → investing reconciliation: $19,786,000.00Other → investing reconciliation: $2,039,000.00investing reconciliation → Acquisitions of financial royalty assets: $2,505,701,000.00investing reconciliation → Purchases of available for sale debt securities: $150,000,000.00investing reconciliation → Milestone payments: $75,000,000.00investing reconciliation → Purchases of equity securities: $62,500,000.00investing reconciliation → Acquisitions of other financial assets: $18,000,000.00investing reconciliation → Investments in equity method investees: $10,955,000.00Net cash used in investing activities → investing reconciliation: $2,678,115,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $477,010,000.00Net cash from operating activities → Cash sources and uses: $2,768,986,000.00Net cash from financing activities → Cash sources and uses: $361,145,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $929,026,000.00Cash sources and uses → Net cash used in investing activities: $2,678,115,000.00Cash collections from financial royalty assets: $2,983,410,000.00Financial royalty collections+$2.98 BCash collections from intangible royalty assets: $14,647,000.00Intangible royalty collections+$14.65 MOther royalty cash collections: $108,846,000.00Other royalty cash collections+$108.85 MInterest received: $46,482,000.00Interest received+$46.48 MDistributions from equity method investees: $13,396,000.00Equity-method distributions+$13.40 MDevelopment-stage funding payments - ongoing: -$2,000,000.00Development-stage funding payments - ongoing−$2.00 MPayments for operating and professional costs: -$236,225,000.00Operating & professional costs−$236.23 MInterest paid: -$159,570,000.00Interest paid−$159.57 MDevelopment-stage funding payments - upfront and milestone: $0.00Net cash from operating activities: $2,768,986,000.00Operating cash+$2.77 Boperating reconciliation: $3,166,781,000.00Distributions to legacy non-controlling interests - Portfolio Receipts: -$362,280,000.00Distributions to legacy non-controlling interests -Portfolio Receipts−$362.28 MDistributions to continuing non-controlling interests: -$125,159,000.00Paid to noncontrolling interests−$125.16 MDividends to shareholders: -$376,465,000.00Dividends to shareholders−$376.47 MContributions from non-controlling interests - other: $4,360,000.00From noncontrolling, other+$4.36 MDistributions to legacy non-controlling interests - other: $0.00Other: -$9,026,000.00Other financing, net−$9.03 MProceeds from issuance of long-term debt, net of discount: $1,471,235,000.00Other long-term debt issued+$1.47 BRepayment of revolving credit facility: $0.00Proceeds from revolving credit facility: $0.00Contributions from legacy non-controlling interests - R&D: $747,000.00From legacy noncontrolling, R&D+$747.00 KDebt issuance costs and other: -$12,616,000.00Debt issuance costs−$12.62 MRepurchases of Class A ordinary shares: -$229,651,000.00Common stock repurchases−$229.65 MCash acquired in connection with purchase of non-controlling interest: $0.00Repayment of long-term debt: $0.00Net cash from financing activities: $361,145,000.00Financing cash+$361.15 Mfinancing reconciliation: $1,476,342,000.00Distributions from equity method investees: $23,641,000.00Equity-method return of capital+$23.64 MPurchases of available for sale debt securities: -$150,000,000.00AFS securities purchases−$150.00 MPurchases of equity securities: -$62,500,000.00Purchases of equity securities−$62.50 MProceeds from available for sale debt securities: $19,786,000.00AFS securities sales+$19.79 MPurchases of marketable securities: $0.00Proceeds from sales and maturities of marketable securities: $0.00Investments in equity method investees: -$10,955,000.00Equity-method investments made−$10.96 MAcquisitions of financial royalty assets: -$2,505,701,000.00Finance receivable purchases−$2.51 BMilestone payments: -$75,000,000.00Milestone payments−$75.00 MProceeds from equity securities: $98,575,000.00Proceeds from equity securities+$98.58 MAcquisitions of other financial assets: -$18,000,000.00Other investment purchases−$18.00 MOther: $2,039,000.00Other investing, net+$2.04 MNet cash used in investing activities: -$2,678,115,000.00. Cash required to fund net payments.Investing cash−$2.68 Binvesting reconciliation: $2,822,156,000.00Cash sources and uses: $3,607,141,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $477,010,000.00Beginning cash$477.01 MEnding cash: Cash, cash equivalents, and restricted cash: $929,026,000.00Ending cash$929.03 MCASH RECONCILIATIONOperatingflowsFinancingflowsInvestingflowsFree cash flowNot availableCash flow / Net incomeUnavailableOperating cash flow ÷ net incomeNet cash change+$452.02 MEnding cash − beginning cash
Chart details

Royalty Pharma plc cash flow reconciliation, Jan 1, 2024 through Dec 31, 2024

Cash flows for Jan 1, 2024 through Dec 31, 2024. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Dec 31, 2023. Ending cash: Dec 31, 2024. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Dec 31, 2023
477,010,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
2,768,986,000 US dollars. Net cash provided.
Cash collections from financial royalty assets
2,983,410,000 US dollars
Cash collections from intangible royalty assets
14,647,000 US dollars
Other royalty cash collections
108,846,000 US dollars
Interest received
46,482,000 US dollars
Distributions from equity method investees
13,396,000 US dollars
Development-stage funding payments - ongoing
negative 2,000,000 US dollars
Payments for operating and professional costs
negative 236,225,000 US dollars
Interest paid
negative 159,570,000 US dollars
Development-stage funding payments - upfront and milestone
0 US dollars
Investing activities
negative 2,678,115,000 US dollars. Net cash used.
Distributions from equity method investees
23,641,000 US dollars
Purchases of available for sale debt securities
negative 150,000,000 US dollars
Purchases of equity securities
negative 62,500,000 US dollars
Proceeds from available for sale debt securities
19,786,000 US dollars
Purchases of marketable securities
0 US dollars
Proceeds from sales and maturities of marketable securities
0 US dollars
Investments in equity method investees
negative 10,955,000 US dollars
Acquisitions of financial royalty assets
negative 2,505,701,000 US dollars
Milestone payments
negative 75,000,000 US dollars
Proceeds from equity securities
98,575,000 US dollars
Acquisitions of other financial assets
negative 18,000,000 US dollars
Other
2,039,000 US dollars
Financing activities
361,145,000 US dollars. Net cash provided.
Distributions to legacy non-controlling interests - Portfolio Receipts
negative 362,280,000 US dollars
Distributions to continuing non-controlling interests
negative 125,159,000 US dollars
Dividends to shareholders
negative 376,465,000 US dollars
Contributions from non-controlling interests - other
4,360,000 US dollars
Distributions to legacy non-controlling interests - other
0 US dollars
Other
negative 9,026,000 US dollars
Proceeds from issuance of long-term debt, net of discount
1,471,235,000 US dollars
Repayment of revolving credit facility
0 US dollars
Proceeds from revolving credit facility
0 US dollars
Contributions from legacy non-controlling interests - R&D
747,000 US dollars
Debt issuance costs and other
negative 12,616,000 US dollars
Repurchases of Class A ordinary shares
negative 229,651,000 US dollars
Cash acquired in connection with purchase of non-controlling interest
0 US dollars
Repayment of long-term debt
0 US dollars
Operating adjustment reconciliation
3,166,781,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
1,476,342,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
2,822,156,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
0 US dollars
Ending cash on Dec 31, 2024
929,026,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
3,607,141,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
452,016,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
Unavailable. Operating cash flow and reconciliation net income for the same period are required.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
Royalty Pharma plc (RPRX) FY2024 Annual Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!